Amgen Inc. (AMGN) Tuesday reported encouraging results from its Phase 2 study of MariTide in people with obesity.
Results from the 2 study showed that MariTide reduced weight up to 20 percent without a weight loss plateau in people with obesity and without Type 2 diabetes at week 52.
In people with Type 2 diabetes, MariTide could reduce weight up to 17 percent, also without a weight loss plateau.
The ongoing part 2 of the Phase 2 study is investigating MariTide beyond 52 weeks to evaluate further weight loss, weight maintenance, and durability of weight loss after discontinuation of treatment.
The company plans to initiate a Phase 3 study dubbed MARITIME in obesity and related conditions.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.